📊 RAPH Key Takeaways
Is Raphael Pharmaceutical Inc. (RAPH) a Good Investment?
Raphael Pharmaceutical is technically insolvent with negative stockholders' equity of -1.4M and zero revenue generation, indicating fundamental operational failure in a pharmaceutical development or commercialization context. The company is experiencing critical liquidity distress with a 0.03x current ratio and negative free cash flow of -211K, leaving approximately one quarter of cash runway at current burn rates, making near-term survival dependent on external capital injection.
Why Buy Raphael Pharmaceutical Inc. Stock? RAPH Key Strengths
- Net losses improved 15.8% YoY, indicating cost reduction efforts
- Minimal operating burn rate of 210K suggests operational wind-down or significant restructuring
- Cash position of 45K preserved despite insolvency, indicating some liquidity management
RAPH Stock Risks: Raphael Pharmaceutical Inc. Investment Risks
- Technical insolvency: negative stockholders' equity of -1.4M means liabilities exceed assets
- Zero revenue with negative operating income of -1.2M indicates complete lack of commercial viability
- Critical liquidity crisis: 0.03x current ratio means total liabilities > 1000x current assets
- Negative free cash flow with <1 quarter of cash runway creates existential survival risk
- Company may lack viable business operations or viable product pipeline
- Massive negative ROA of -2413% indicates severe economic value destruction
Key Metrics to Watch
- Revenue generation or any commercial milestone achievement
- Stockholders' equity trend and capital injection announcements
- Operating cash flow trajectory and cash burn rate
- Form 4 insider filings indicating management confidence changes
Raphael Pharmaceutical Inc. (RAPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RAPH Profit Margin, ROE & Profitability Analysis
RAPH vs Materials Sector: How Raphael Pharmaceutical Inc. Compares
How Raphael Pharmaceutical Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Raphael Pharmaceutical Inc. Stock Overvalued? RAPH Valuation Analysis 2026
Based on fundamental analysis, Raphael Pharmaceutical Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Raphael Pharmaceutical Inc. Balance Sheet: RAPH Debt, Cash & Liquidity
RAPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Raphael Pharmaceutical Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.08 reflects profitable operations.
RAPH Revenue Growth, EPS Growth & YoY Performance
Raphael Pharmaceutical Inc. Dividends, Buybacks & Capital Allocation
RAPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Raphael Pharmaceutical Inc. (CIK: 0001415397)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RAPH
What is the AI rating for RAPH?
Raphael Pharmaceutical Inc. (RAPH) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RAPH's key strengths?
Claude: Net losses improved 15.8% YoY, indicating cost reduction efforts. Minimal operating burn rate of 210K suggests operational wind-down or significant restructuring.
What are the risks of investing in RAPH?
Claude: Technical insolvency: negative stockholders' equity of -1.4M means liabilities exceed assets. Zero revenue with negative operating income of -1.2M indicates complete lack of commercial viability.
What is RAPH's revenue and growth?
Raphael Pharmaceutical Inc. reported revenue of N/A.
Does RAPH pay dividends?
Raphael Pharmaceutical Inc. does not currently pay dividends.
Where can I find RAPH SEC filings?
Official SEC filings for Raphael Pharmaceutical Inc. (CIK: 0001415397) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RAPH's EPS?
Raphael Pharmaceutical Inc. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RAPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Raphael Pharmaceutical Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RAPH stock overvalued or undervalued?
Valuation metrics for RAPH: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy RAPH stock in 2026?
Our dual AI analysis gives Raphael Pharmaceutical Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RAPH's free cash flow?
Raphael Pharmaceutical Inc.'s operating cash flow is $-210.0K, with capital expenditures of $1.0K.
How does RAPH compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio 0.03 (avg: 1.6).